Theratechnologies Soars 78.57% on FDA Approval of EGRIFTA WR™

On March 26, 2025, Theratechnologies' stock surged by 78.57% in pre-market trading, marking a significant rise that has captured the attention of investors and analysts alike.

Theratechnologies has received FDA approval for EGRIFTA WR™ (Tesamorelin F8), a new formulation designed to treat excess visceral abdominal fat in adults with HIV and lipodystrophy. This approval is a major milestone for the company, as it represents the first medication of its kind approved in the U.S. for this specific indication. The new formulation, EGRIFTA WR™, offers a more convenient administration schedule, requiring weekly reconstitution instead of daily, which is expected to improve patient compliance and overall experience.

The approval of EGRIFTA WR™ is anticipated to have a positive impact on Theratechnologies' market position and financial performance. The new formulation's convenience and efficacy are likely to drive increased adoption among healthcare providers and patients, potentially leading to higher sales and revenue growth. Additionally, the patent protection for EGRIFTA WR™ until 2033 provides the company with a competitive advantage in the market.

Theratechnologies' management has expressed optimism about the new formulation, highlighting its potential to improve the management of comorbidities like lipodystrophy in HIV patients. The company's focus on innovative therapies and its commitment to enhancing patient outcomes are expected to continue driving its growth and success in the biopharmaceutical industry.